

**Amendments to the Claims:**

**This listing of claims will replace all prior versions and listings of claims in the application.**

**Listing of Claims:**

1-8. (canceled).

9. (withdrawn) A drug kit comprising a carrier cell for gene therapy in treating cancer including a carrier cell to be infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein both A549 cell and 293 cell are together used as the carrier cell.

10. (canceled).

11. (currently amended) A drug kit for cancer gene therapy comprising:  
a vaccine comprising a tumor cell, wherein the vaccine which is administered to a living body prior to a carrier cell, to perform tumor vaccination, and  
a carrier cell infected with an oncolytic virus for administration to the living body,  
wherein the oncolytic virus targets so as to make the oncolytic virus act on a tumor cell within the living body, and wherein the carrier cell is an A549 cell, and  
a virus for immunological treatment.

12. (new) The drug kit according to claim 11, wherein the oncolytic virus has a promoter selected from the group consisting of 1A1.3B promoter, midkine promoter, β-HCG promoter, SCCA1 promoter, cox-2 promoter, PSA promoter and a tumor specific promoter according to kind of cancer to be treated.

13. (new) The drug kit according to claim 11, wherein the oncolytic virus and the virus for immunological treatment are independently selected from the group consisting of adenovirus, herpes virus, lentivirus, HIV virus, retrovirus, reovirus, and vesicular stomatitis virus (VSV).

14. (new) The drug kit according to claim 11, wherein the virus for immunological treatment induces a CTL reaction within the living body upon administration, and wherein the virus for immunological treatment is administered prior to administration of the carrier cell.

15. (new) The drug kit according to claim 11, further comprising atelocollagen.

16. (new) The drug kit according to claim 11, further comprising a GM-CSF expression vector to be transfected into the carrier cell before carrier cell administration.

17. (new) The drug kit according to claim 11, further comprising an iron preparation and/or a porphyrin compound.

18. (new) The drug kit according to claim 14, wherein the virus for immunological treatment is selected from the group consisting of adenovirus, herpes virus, lentivirus, HIV virus, retrovirus, reovirus, and vesicular stomatitis virus (VSV).

19. (new) The drug kit according to claim 11, wherein the carrier cell further comprises a GM-CSF expression vector.

20. (new) The drug kit according to claim 11, wherein the virus for immunological treatment is an inactivated virus.